Peptide Receptor Radionuclide Therapy (PRRT) With Radiolabelled Somatostatin Analogue 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors, 18F-2-fluoro-2-deoxy-D-glucose (FDG)-PET Negative Patients: a Prospective Phase II Randomized Study
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 19 Jul 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2020.
- 15 Dec 2015 New source identified and integrated (NCT02489604).
- 15 Dec 2015 New trial record